Invest on your own
Build your own portfolio, stock by stock.
We do it for you
Professionally managed portfolios, built and rebalanced for you.
NEW
How we screen every stock
Our halal screening & purification process in 3 minutes
Screeners
Your portfolio
Calculators
TOOL
Check any stock in seconds
Search 11,000+ tickers and see the halal verdict instantly.
Our certifications
Independent proof that every stock and portfolio meets halal standards.
METHODOLOGY
How we screen every stock
Our 5-step halal methodology, in 90 seconds.
Get help
NEW
Halal investing 101
A beginner-friendly intro to investing the halal way.
Plans by product
COMPARE
Find your plan
See every feature side-by-side and pick what fits.
Investors
INVESTORS
Invest in Musaffa
We're building the financial house for 1.9B Muslims. See the deck.
EIKN Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: May 23, 2026
Report Source: 2026 1st Quarter Report
Eikon Therapeutics Inc. Stock Analysis EIKN
United States Health Care Small Cap Report: Eikon Therapeutics is a biopharmaceutical company. The company is headquartered in Millbrae, California and currently employs 384 full-time employees. The company went IPO on 2026-02-05. The firm has clinical programs at various stages of development, and active discovery efforts in oncology and neurological disease. Its pipeline includes EIK1001 TLR7/8 Melanoma, EIK1001 TLR7/8 NSCLC, EIK1003 PARP1, EIK1004 PARP1, EIK1005 WRN Phase 1, EIK1006, and AR-V7. EIK1001 is a systemically administered dual-agonist of toll-like receptors 7 and 8 that has demonstrated single-agent activity, as well as activity in combination with anti-PD-(L)1 agents, across multiple solid tumor types in Phase 1 trials. EIK1003 targets PARP1, a central component of DNA repair machinery in normal cells. EIK1003 is being evaluated in a Phase 1/2 study of patients with breast, ovarian, or prostate malignancies that have known or suspected deleterious mutations of select homologous recombination repair (HRR) genes.
Read More Eikon Therapeutics Inc (EIKN) Chart
Key Statistics of Eikon Therapeutics Inc (EIKN)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$9.70Volume
223.30KP/E Ratio (TTM)
-52 Week Range
Market Cap
604.19MAvg. Volume
277.64KDividend Yield
-Financial Metrics & Statements of Eikon Therapeutics Inc (EIKN)
FAQ's for Eikon Therapeutics Inc (EIKN)
- According to Musaffa’s Shariah screening methodology, Eikon Therapeutics Inc (EIKN) is currently classified as NOT HALAL as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Eikon Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Eikon Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Eikon Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Eikon Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Eikon Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.